Candel Therapeutics Inc (NASDAQ:CADL) has provided a corporate update, highlighting anticipated milestones for this year building upon significant achievements in 2024.   Updated overall survival data...

Best-Performing Stocks Of 2024

In the New Year, many small-cap biotech companies will be advancing promising clinical trials with innovative therapies aimed at addressing significant unmet medical needs. Key trials include those fo...

Candel Therapeutics Inc (NASDAQ:CADL) shares skyrocketed by nearly 43% on Thursday following a string of positive news surrounding the company's cancer drug pipeline. Last week the Needham, Massachuse...

Candel Therapeutics Inc (NASDAQ:CADL) announced on Monday the completion of a public offering that raised approximately $92 million in gross proceeds. The offering included 12 million shares of common...

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 150 points on Friday.

Candel Therapeutics Inc (NASDAQ:CADL) has announced an $80 million underwritten public offering of its common stock and pre-funded warrants. The offering includes approximately 10 million shares of co...

Candel stock rallies 68% on meeting the primary goal in a phase III study of CAN-2409 combo therapy compared to SOC radiation therapy for prostate cancer.

Candel's phase 3 trial for CAN-2409 in high-risk prostate cancer met its primary endpoint, showing a 14.5% improvement in disease-free survival over placebo. Financially, CADL holds $16.6 million in c...

Candel Therapeutics Inc (NASDAQ:CADL) is soaring today, up 164% at $12.17 at last glance and earlier hitting a three-year high of $14.60, after the biotech company's prostate cancer immunotherapy trea...

On Wednesday, Candel Therapeutics, Inc. CADL announced results from a phase 3 trial of CAN-2409 viral immunotherapy in intermediate-to-high-risk, localized prostate cancer patients.

Shares of Candel Therapeutics skyrocketed Wednesday after the biotech company's prostate cancer treatment succeeded in a Phase 3 study. The post Candel Skyrockets By Triple Digits On A Potential First...

Candel Therapeutics Inc (NASDAQ:CADL) announced that its experimental immunotherapy, CAN-2409, met its main goal in a Phase 3 trial, significantly improving disease-free survival in patients with loca...

Candel Therapeutics said on Wednesday its experimental prostate cancer drug met the main goal of a late-stage trial, sending the company's shares up 64% in premarket trading.

Cancer treatment has long been dominated by traditional approaches such as surgery, radiation, and chemotherapy. But in recent years, a wave of innovation has emerged, driven by the promise of immunot...

In the biopharmaceutical world, where innovation and breakthroughs often dominate headlines, a fundamental question is frequently overlooked: are we truly listening to patients? For Paul Peter Tak CEO...

Candel Therapeutics Inc (NASDAQ:CADL) CEO Paul Peter Tak expressed optimism for a "paradigm shift" in prostate cancer treatment as the biopharmaceutical company moves closer to phase 2b and phase 3 tr...

Candel Therapeutics Inc (NASDAQ:CADL) recently presented insights into its oncolytic virus therapy, CAN-3110, at the Society for Immunotherapy of Cancer (SITC) conference. The company's Chief Scientif...

Candel Therapeutics Inc (NASDAQ:CADL) announced that preclinical data from its CAN-3110 program indicate promising antitumor activity in melanoma, suggesting a potential expansion beyond the candidate...

Candel Therapeutics is working on intratumoral oncolytic virus therapy. A pair of mid to late-stage trials in prostate cancer are expected to read out in Q4. Positive findings could be the position of...